#nucmed — Public Fediverse posts

RT @officialEANM: Curious about #NucMed challenges on research infrastructures & nuclear competences?

Check out @EU_ScienceHub report on Third 🇪🇺 High Level Nuclear Roundtable on Medical Applications

📝Roadblocks preventing technological advances from reaching patients

👉https://publications.jrc.ec.europa.eu/repository/handle/JRC133078 https://t.co/B5Hy6yvbZE

🐦🔗: https://n.respublicae.eu/EU_ScienceHub/status/1654105540664999937

Lots of folks in #nucmed and #radonc are interested in launching their own #radiopharmaceuticals ☢️therapy program, but not sure where to start.

If you're in this camp, you're in luck!🍀

@[email protected] and the team @[email protected] put together this comprehensive guide!

👇👇👇

https://onlinelibrary.wiley.com/doi/abs/10.1002/acm2.13899

@Kmachel

Did you see this yet?

https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-1931/711352/Gallium-68-labeled-Peptide-PET-Quantifies-Tumor

#nucmed #radonc #oncodon #oncology

Press release on PSMAfore trial, a ph3 study of pts with mCRPC randomized to switch of androgen receptor pathway inhibitor or 177Lu-PSMA tx.

✅1° endpt of sig improvement in radiographic PFS met
✅ no unexpected safety findings

https://www.novartis.com/news/media-releases/novartis-pluvictotm-shows-statistically-significant-and-clinically-meaningful-radiographic-progression-free-survival-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer

#Radiopharmaceuticals #Oncology #NucMed #RadOnc #ProstateCancer

@Kmachel

Nice! This recent paper in JACS might be of interest then: https://pubs.acs.org/doi/full/10.1021/jacs.2c08438

#oncology #radiopharmaceuticals #radonc #nucmed

#NET peeps might find the work of interest
@[email protected] @[email protected] @[email protected] @[email protected] @[email protected] @[email protected] @[email protected] @[email protected] @[email protected] @[email protected]

#radonc #nucmed #radiopharmaceuticals #NETresearch

11/

Lu-dotatate changed how patients with SSTR+ NETs are treated.

Still, many patients have NETs that don’t respond or develop resistance to Lu-dotatate
#radiopharmaceuticals therapy.

Could alpha particle therapy help?

🧵 1/

@[email protected] @[email protected] #nucmed #radonc #oncology

Hello former #medtwitter and now #medmastodon

I am a trained ☢️ #radiochemist 🧪 who wants to stay on top of ☢️ #nucmed 💉🩺

So anybody who works with #PET #SPECT #PRRT #TRT or and especially #TAT feel free to reach out and discuss 💪☺️

So I am very excited to be part of a new #nuclearmedicine network here 🤗

#introductions

Hi Mastodonians, MastoDons, & MastoDoñas!

I am an oncologist and scientist at the NCI developing #radiopharmaceuticals in the lab to help image and treat cancer.

My research sits at the interface of #oncology #chemistry #radiochemistry #DrugDevelopment #ClinicalTrials #nucmed #radonc.

Beyond the professional, I enjoy #audiobooks, #fitness, #coffee, and occasional #beer #homebrewing.

Looking to connect with and learn from diverse thinkers in oncology, medicine, and beyond.